Pure Global
NCT06414031

Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

Tranexamic Acid for Reduction of Intra- and Postoperative Transfusion Requirements in Elective Abdominal Surgery: Randomized Controlled Trial
Ulrich Ronellenfitsch, MD·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Surgical Blood Loss,Transfusion-dependent Anemia,Abdomen Disease
Drug/Device/Intervention
Tranexamic Acid
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ulrich Ronellenfitsch, MD
Funder
Martin-Luther-Universität Halle-Wittenberg
Location
Halle (Saale), Germany
Timeline & enrollment
Phase
Phase 3
Start date
Jun 01, 2024
End date
Nov 30, 2025
Enrollment
850 participants
Primary outcome

Transfusion necessity

Summary

The goal of this clinical trial is to learn if the administration of tranexamic acid can
 reduce the necessity of blood transfusions in adult patients undergoing major abdominal
 surgery. . It will also inform about safety of tranexamic acid in this setting.
 
 The main question it aims to answer is: Does tranexamic acid lower the probability of
 receiving at least one blood transfusion during or after surgery?
 
 Participants will compare tranexamic acid o a placebo (a look-alike substance that contains
 no drug) to see if tranexamic acid works to reduce the necessity of a blood transfusion.

ICD-10 classifications
Blood transfusion (without reported diagnosis)Congenital anaemia from fetal blood lossIron deficiency anaemia secondary to blood loss (chronic)Other anaemiasOther complications following infusion, transfusion and therapeutic injection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414031
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414031 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ulrich Ronellenfitsch, MD and is currently Not yet recruiting. The study focuses on Surgical Blood Loss,Transfusion-dependent Anemia,Abdomen Disease. Target enrollment is 850 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.